Mehdi Ainouche, PharmD

Mehdi Ainouche, PharmD, is a Partner at Jeito Capital, based in Paris, with over a decade of experience in life sciences investing. He has played a key role in numerous investments and supported portfolio companies across a range of therapeutic areas, including ophthalmology, oncology, CNS, cardiometabolic, and neuromuscular diseases. He currently serves on the boards of CDR-Life and Augustine Therapeutics, is a board observer at NMD Pharma, and previously held an observer role at EyeBio (acquired by Merck).

Mehdi joined Jeito Capital (global leading independent Private Equity fund, with €534 million under management based in Paris & NYC) in 2020.

Prior to Jeito, Mehdi’s last role was Associate within the healthcare venture team of Turenne Capital, a French investment group with over €2Bn under management, where he successfully participated to several investments in biotech & medtech.

Mehdi holds a Pharmacy Doctorate from University of Rennes (France) and a Master in Business from ESCP Europe Business School Paris.